China Biotechnology Service (08037) Announces Initial Follow-up Results of Boron Neutron Therapy at the 22nd Academic Conference of the Japanese Society of Neutron Capture Therapy

Zhitong Finance App News, China Biotechnology Service (08037) announced that at the 22nd Japan Society of Neutron Capture Therapy Academic Conference (JSNCT22) held at Kyoto University in Japan, the company's subsidiary, Pengbo (Hainan) Boron Neutron Medical Technology Co., Ltd. published in the form of an oral report the first 10 cases of head and neck cancer patients who received boron neutron capture therapy (boron neutron therapy) for the first 10 cases of head and neck cancer who received boron neutron capture therapy (boron neutron therapy) three months (90 days) after treatment.

Results showed that when the first 10 evaluable patients were followed up for 3 months (90 days) after treatment, a total of 8 cases were confirmed to be effective. Among them, the complete remission rate (that is, the target tumor completely disappeared, no new lesions appeared, and related clinical indicators returned to normal) was 40% (4 cases out of 10); the partial remission rate (that is, the total diameter of the target tumor decreased by 30% or more, and no new lesions appeared) was 40% (4 out of 10 cases), and the clinical effect was remarkable.

Pengbo Hainan Hospital is the Group's flagship project located in the Lecheng International Medical Tourism Pilot Zone in Boao, Hainan, China. It entered trial operation in February 2026 and began patient treatment for the first time in March 2026. Dozens of cases have been treated so far. Taking advantage of the policy advantages of the Hainan Boao Lecheng International Medical Tourism Pilot Zone, the Group introduced the world's first approved boron neutron therapy device NeuCure® neutron irradiation system and the world's first approved boron neutron therapy drug Steboronine® to provide safe and accurate boron neutron therapy services for cancer patients.